Eli Lilly's Strategic Pivot: Expanding Access to Drive Growth

Eli Lilly launches 'Employer Connect' to help companies cover weight-loss drugs, addressing a major barrier to patient access and affordability for Zepbound.

Pharmaceutical giant Eli Lilly is tackling a fundamental barrier to growth for its weight-loss medication Zepbound: patient access through employer-sponsored insurance. The company's latest initiative aims to address a systemic gap in the U.S. healthcare landscape that frequently prevents insured individuals from starting or continuing obesity treatments. For Lilly, the challenge extends beyond generating demand; it centers on ensuring patients can actually afford the therapy.

A New Platform for Employer Solutions

This week, the company launched "Employer Connect," a platform designed to help employers more easily establish transparent programs for providing obesity medications to their workforce. This is done in collaboration with independent program administrators.

The move targets a core structural issue in the United States, where high costs and inconsistent insurance coverage create significant hurdles. According to Lilly's data, approximately half of commercially insured individuals are unable to begin or maintain a course of obesity medication treatment due to these barriers. This represents a major impediment to commercial success, even amidst substantial underlying medical demand.

Transparent Pricing to Build Confidence

A key feature of the platform is a simplified pricing model for the Zepbound (tirzepatide) KwikPen. It is offered to network pharmacies at a reduced price of $449 for all dosages, explicitly without rebates. This approach is intended to provide employers with greater budgeting certainty by making the net price more visible and predictable.

Employers utilizing the platform can select from more than 15 administration partners. Services range from basic functions like enrollment, eligibility verification, and billing to comprehensive obesity management programs that include telemedicine, nutritional counseling, and lifestyle support. The offering is particularly aimed at companies that have been hesitant to cover these drugs. An October survey cited in the report found that less than one-fifth of firms with over 200 employees provided coverage for GLP?1 weight-loss drugs. For very large employers (5,000+ employees), the figure was higher at 43%.

Market observers view this strategy as an incremental advancement, but one that signals a clear shift in industry dynamics. Whereas drug manufacturers and Pharmacy Benefit Managers historically opposed external discount models, GLP?1 producers are now increasingly working with such frameworks to broaden patient access.

Analyst Support and a Concentration Challenge

Separately, Deutsche Bank reaffirmed its Buy rating for Eli Lilly shares on Friday, though it did not issue a new price target. The bank's report cited aggregated prescription data as supporting confidence in continued volume growth.

This optimism aligns with strong financial projections for 2025, which forecast revenue of $65.2 billion (a 45% increase) and earnings per share (EPS) of $24.21 (up 86%). The company's incretin-based products have been the primary growth drivers: sales of Mounjaro and Zepbound surged by 99% and 175% respectively in 2025, accounting for nearly all of the company's growth.

This success, however, reveals a structural vulnerability: the two GLP?1 products now represent 56% of total revenue. The eventual expiration of patent protection will inevitably create a gap that Lilly must fill with new innovations.

Pipeline: Oral Therapies and Next-Generation Compounds

Looking beyond its injectable blockbusters, Eli Lilly is banking on its development pipeline for sustained momentum. A major focus is orforglipron, an oral GLP?1 agonist. Following successful Phase 3 trials, the company awaits a regulatory decision from the U.S. FDA, with submissions also underway in Japan and the European Union for both obesity and type?2 diabetes. A U.S. launch for chronic weight management is anticipated in the second quarter of 2026, with most international markets following in 2027.

Further back in the pipeline is retatrutide, a once-weekly injectable that targets GIP, GLP?1, and glucagon receptors. Phase 3 data reported in the article were positive, including results for obesity patients with knee osteoarthritis. Additionally, seven more Phase 3 readouts are scheduled throughout 2026, including data on maintenance dosing.

On a weekly basis, Eli Lilly's share price has faced notable pressure, declining 4.24% over the past seven days.

The calendar for the coming year highlights critical catalysts. The ongoing second quarter of 2026 is poised to be decisive, featuring the next steps for orforglipron (the FDA decision and expected U.S. launch) alongside the promised Phase 3 data points for retatrutide. This period will be crucial for Lilly to demonstrate that its growth trajectory is not permanently dependent on just two GLP?1 products.